Therapeutic Role of Different Enzymes and Inhibitors in Alzheimer’s Disease Management
A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".
Deadline for manuscript submissions: closed (15 December 2022) | Viewed by 2509
Special Issue Editor
Special Issue Information
Dear Colleagues,
Alzheimer’s disease (AD) is a predominant neurodegenerative disorder and the principal cause of dementia, affecting a large population worldwide. AD is characterized by the loss of memory and learning ability in the elderly population. Therefore, it is fundamental to seek new strategies for AD therapy for the adult population. In this regard, natural and synthetic compounds and peptides are being currently used as therapeutic agents. The different target enzymes, such as acetylcholinesterase (AChE), butyrylcholinesterase (BuChE), monoamine oxidases (MAO), β-secretase, and γ-secretase, are the key enzymes responsible for the development of AD. The development of different strategies targeting these enzymes for the management of AD would be beneficial for the elderly population. Currently, natural compounds are being utilized extensively with no or minimum toxicity against these targets for the effective management of AD.
This Special Issue aims to provide an overview of recent studies focused on innovative approaches to treat AD by targeting these enzymes with the help of molecules and drugs as candidates for developing anti-AD drugs.
Original papers, short communications, and review articles in this Special Issue may cover multidisciplinary aspects related to in silico, in vitro, and in vivo experiments.
Dr. Syed Sayeed Ahmad
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- neurodegenerative disorder
- alzheimer’s disease
- acetylcholinesterase
- butyrylcholinesterase
- monoamine oxidases
- β-secretase
- γ-secretase
- synthetic inhibitors
- natural product inhibitors
- drug discovery
- molecular docking
- molecular dynamics simulation
- structure–activity relationships
- molecular modeling
- biological activity
- enzyme kinetics
